Fig. 2From: A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemiaResponse rates per BCR-ABL1IS ratios in patients receiving imatinib (navy), nilotinib (azure) or dasatinib (light blue) as 1 L TKI.a aOnly detectable BCR-ABLIS ratios were included in this analysis. 1 L, first line; IS, International Scale; TKI, tyrosine kinase inhibitorBack to article page